drugset / Trial / NCT04445363

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata

NCT04445363

Phase 1/2 Unknown 160 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This study includes a dose escalation part(phase I) and a dose extension part(phase II).

Timeline

Start
2020-08-12
Primary completion
2024-12-01
Completion
2024-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown 0.5 % Topical
Subject Jaktinib Unknown 1.5 % Topical
Subject Jaktinib Unknown 2.5 % Topical

Indications